Kornimate/medical-research-clean huggingface dataset:
genomic screening for hereditary erythrocytosis and related diseases

Conditions: Hereditary Erythrocytosis/Idiopathic Erythrocytosis

Summary: unexplained polycythemias are rare diseases, and therefore, the collection of data inherent to these diseases will not only improve their characterisation, but also allow stratification according to the risks and the course of the disease. the objective of this project is to constitute a database on the disease which will allow us to better understand it and in due course improve its management. the genred project thus bears uniquely on the collection of information, which will be gathered throughout the usual management of patients for this type of disease.


Eligibility criteria:
inclusion criteria: the characteristics of the patients included in the database will be described in terms of numbers and percentages for qualitative variables and in terms of means and standard deviations or medians and interquartile intervals for quantitative variables. exclusion criteria: the first step will be to exclude acquired secondary (pulmonary, renal and cardiac) or acquired primary (polycythemia vera due to jak2 mutations) causes. the family history and the determination of serum epo levels are very useful in the decision regarding which molecular tests should be performed first. * patients without absolute erythrocytosis (i.e. without an increased red cell mass \>125% of mean predicted value, or if the haematocrit is \<60% in males or \<56% in females. * erythrocytosis related to polycythemia vera according to the 2008 who (world health organization) criteria * secondary erythrocytosis related to an obvious cause (renal lesions, chronic lung or heart diseases, endocrine lesions, miscellaneous tumours producing epo, drugs such as androgens, hepatic lesions...) * low venous blood p50: the determination of p50 (percentage at which hb is half saturated with oxygen) is very helpful is establishing the presence of a haemoglobin variant with high oxygen affinity or a rare 2,3-diphosphoglycerate (2,3-dpg) deficiency. in such a situation, a specific hbb, hba1 and hba2 mutation will be screened for using sanger sequencing (these genes are not included in ngs analysis because of redundancy of pseudogenes). in order to rule out non-informative erythrocytosis cases, a form including mandatory further tests must be filled in for a selection step. the required tests are: complete blood counts * blood electrolytes * arterial and venous gazes * serum erythropoietin dosage * liver function tests * jak2 mutations (both v617f and exon 12) * bone marrow aspirate and/or biopsy and/or endogenous bfu-e culture * abdominal ultrasound * lung function tests
gst-moms: effects of group-schematherapy on mother-child attachment relations

Conditions: Cluster C Personality Disorder (Diagnosis); Mother-Child Relations

Summary: the birth of a baby can be a stressful period. dysfunctional schemas of the 'new' parent can be triggered making it more difficult to discern what the baby needs are. in schema therapy terms, mentalizing capacity is best described as the "healthy adult mode". a parent who responds to her baby from a healthy adult mode provides the baby a safe environment for self-development. however, interpreting the baby's signals can be a constant challenge for some parents. this can trigger early attachment relationships and schemas. at such times, the parent may become overwhelmed by their own emotions and respond less adequate to the child's needs. distorted parental reflective functioning is associated both with insecure attachment and poor affect regulation in the parent and with various psychological disorders in the child. treatments aimed at improving parental reflectiveness seem to have a positive impact on the quality of the attachment between parents and their baby. the objective of this study is to measure the effects of the group-schematherapy for mothers with young children (gst moms) on mother-child attachment relations. the aim is to help moms regulate their own emotions, by understanding their own modes and schema's. in doing so will help them feel more confident to mentalize about their child and to adequately respond to their needs and emotionally bond with their baby. the researchers anticipate it will improve the quality of attachment between mother and child. many studies have been done on the effectiveness of group schematherapy however there are no studies specifically for schematherapy for parents, in this case mothers. gst moms can be an early intervention aimed at prevention of psychological problems with the child.


Eligibility criteria:
inclusion criteria: * eligible patients for the group schematherapy are mothers with young children (0-5 years), with a cluster c personality disorder. exclusion criteria: * acute suicidal or chronic suicidality * psychotic disorder * autistic spectrum disorder * bipolar disorder * developmental disorders * any other as-i disorder that requires treatment first (severe depression, alcohol and/or drugs abuse) * cluster a or b personality disorders (traits of cluster b in combination with cluster c personality disorder is included) * neuropsychological damage * general problems for group therapy (auditory impairment, severe physical disability, insufficant dutch comprehension, iq \< 80) * self-mutilation

Keywords: group schematherapy mother-child attachment effectiviness
cardiorespiratory fitness using electrically assisted bicycles

Conditions: Diabetes Mellitus, Type 2

Summary: this study aimed to examine cycling time and distance when inactive subjects were provided with electrically assisted bicycles, and secondly, to examine changes in cardiorespiratory fitness.

method: inactive employees in a selection of public and private corporations in three norwegian cities were invited to participate. inclusion criteria were: a desire to cycle to work, residence more than 3km from the workplace, and not physically active according to guidelines. there were 25 participants in the study and we provided them all with electrically assisted bicycles fitted with gps bike computers to record usage. the participants were followed for three to eight months, 226 days on average. measures of maximal oxygen uptake were performed before and after the intervention. demographic characteristics and prior transportation habits were reported in a questionnaire at baseline.

Eligibility criteria:
inclusion criteria: -a desire to cycle to work, residence more than 3km from the workplace, and not physically active according to guidelines exclusion criteria: -
an exploratory haemodynamic study in patients with compensated cirrhosis and portal hypertension

Conditions: Compensated Cirrhosis and Portal Hypertension

Summary: the main purpose of this exploratory study was to investigate the effect of serelaxin (rlx030) infusion on the hepatic and renal circulation in patients with compensated cirrhosis and portal hypertension. measurements were acquired non-invasively using magnetic resonance angiography (mra) (study part a) and more directly via cannulation of the hepatic portal vein during a routine transjugular intrahepatic portosystemic shunt (tipss) check procedure (study part b), to determine the acute haemodynamic response to serelaxin (rlx030).


Eligibility criteria:
inclusion criteria: study parts a and b: -cirrhosis of alcohol aetiology according to physician's assessment prior to screening. part a: -cirrhosis with clinical and/or endoscopic evidence of portal hypertension (e.g. oesophageal varices). part b: * cirrhosis with tipss in situ and ppg\>5mmhg. * fully functioning tipss without variceal filling as confirmed by portography. exclusion criteria: study parts a and b: * use of any drug to treat portal hypertension (e.g. vasodilators such as non-selective beta blockers or nitrates) within 1 month prior to screening. * decompensated cirrhosis (child-pugh score \>9 points, and/or ascites requiring diuretics, and/or hepatic encephalopathy) at visit 1. * presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk. part a: * bmi (weight\[kg\] / height\[m\^2\]) \> 40 kg/m\^2. * any contraindication to having an mri scan part b: -contraindication to catheterization

Keywords: portal hypertension, cirrhosis, tipss, mri, mra, portal pressure, portal pressure gradient
the effects of leucine and isoleucine on glucose metabolism

Conditions: Hyperglycemia

Summary: diabetes is classified as an impairment of the body's ability to control blood glucose levels. uncontrolled hyperglycemia can give rise to macrovascular (i.e., heart disease and stroke) and microvasculature damage such as retinopathy, nephropathy and neuropathy. these comorbidities may definitively reduce quality of life. hypotheses to be tested: 1. the ingestion of amino acids l-isoleucine and l-leucine at a therapeutic dose prior to a glucose load will concurrently and independently improve glucose tolerance. 2. the ingestion of l-isoleucine and l-leucine separately or together will have a minimal effect on incretin responses of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide (glp-1, gip).

specific aims and hypothesis diabetes is classified as an impairment of the body's ability to control blood glucose levels. uncontrolled hyperglycemia can give rise to macrovascular (i.e., heart disease and stroke) and microvasculature damage such as retinopathy, nephropathy and neuropathy. these comorbidities may definitively reduce quality of life. hypotheses to be tested: 1. the ingestion of amino acids l-isoleucine and l-leucine at a therapeutic dose prior to a glucose load will concurrently and independently improve glucose tolerance. 2. the ingestion of l-isoleucine and l-leucine separately or together will have a minimal effect on incretin responses (glp-1, gip). specific aims: 1. specific aim i will test the hypothesis that the ingestion of amino acids l-isoleucine and l-leucine at a therapeutic dose prior to a glucose load will concurrently and independently improve glucose tolerance. 2. specific aim ii will test the hypothesis that the ingestion of l-isoleucine and l-leucine will have a minimal effect on incretin responses in conjunction with prior research.

Eligibility criteria:
inclusion criteria: 1. age range of 20 to 40 years of age 2. (sedentary lifestyle) participants whom exercise less than the american college of sports medicine recommendation of weekly physical activity levels or are completely sedentary may be admitted into the study 3. apparently healthy 4. currently not using supplemental branch chain amino acids (bcaa) or whey protein 5. non-smoking exclusion criteria: 1. chronic or acute health problems 2. smoker 3. currently using supplemental bcaa or whey protein -

Keywords: leucine isoleucine
airway pressure release ventilation (aprv) protocol early used in acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: the aim of this study is to assess the effects and safety of the early application of bilevel-aprv protocol and conventional ventilation strategy that used low tidal volume and adequate peep level in ards patients .

although mechanical ventilation is life-sustaining for patients with ards, it can perpetuate lung injury. a number of recent advances have greatly improved in the mechanical ventilation strategies and treatment for acute respiratory distress syndrome (ards), however, mortality remains high, even with the use of low tidal volume and adequate positive end expiratory pressure(peep). numerous experimental showed that the bilevel-aprv mode used in animal ards model can improve gas exchanges and hemodynamic tolerance of the ventilation while reducing the dosage for sedative drugs. the aim of this single-center, prospective, randomized, controlled, open study is to compare the effects and safety of the early application of bilevel-aprv protocol and conventional ventilation strategy that used low tidal volume and adequate peep level in ards patients .

Eligibility criteria:
inclusion criteria: * acute respiratory distress syndrome,according to the berlin definition of ards, - the receipt of endotracheal mechanical ventilation for a period was no longer than 48 hours * a ratio of the partial pressure of arterial oxygen (pao2) to the fraction of inspired oxygen(fio2) was less than 250. exclusion criteria: * pregnancy * the expected duration of mechanical ventilation was less than 48 hours * intracranial hypertension (suspected or confirmed) * neuromuscular disorders that are known to prolong the need for mechanical ventilation * known or suspected chronic obstructive pulmonary disease(copd) * preexisting conditions with an expected 6-month mortality exceeding 50% * pneumothorax (drained or not)at enrollment * treatment with extracorporeal support (ecmo) at enrollment * there was a lack of commitment to life support.
counseling for primary care office-based buprenorphine

Conditions: Opiate Dependence

Summary: the major goal is to determine whether adding cognitive behavioral therapy to physician management will increase the efficacy of buprenorphine/naloxone treatment in an office-based primary care setting.

to evaluate the need for drug counseling aimed at reducing illicit drug use and increasing buprenorphine/naloxone adherence, the proposed study compares manual-guided physician management (pm) and pm combined with on-site manual-guided cognitive behavioral therapy (cbt) in a 24 week randomized clinical trial of buprenorphine/naloxone in a heterogeneous population of opioid dependent patients (n=140) in a primary care clinic. pm, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services. cbt will be provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing buprenorphine/naloxone adherence. the study will test the hypothesis that that the addition of cbt to pm will lead to decreased illicit drug use, durable effects after counseling has been discontinued, improved buprenorphine/naloxone adherence and will demonstrate incremental cost-effectiveness in patients receiving buprenorphine/naloxone maintenance in primary care. primary outcome measures include reductions in illicit opioid use and abstinence achievement, as assessed by weekly urine toxicology testing and self report. secondary outcome measures include retention in treatment, reductions in cocaine use and hiv risk, decreased criminal activity and improved health and employment status. utilization and costs of services, spillover effects in the pcc, and patient and staff perceptions of benefits and problems associated with primary care agonist maintenance treatment will also be evaluated. the results of this study will help define the role of professional evidence-based drug counseling in expanding access to treatment with buprenorphine/naloxone.

Eligibility criteria:
inclusion criteria: * opioid dependence exclusion criteria: * current dependence on alcohol, cocaine, benzodiazepines or sedatives * current suicide or homicide risk * current psychotic disorder or untreated major depression * inability to read or understand english * life-threatening or unstable medical problems

Keywords: buprenorphine buprenorphine/naloxone counseling primary care
treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter malaysia

Conditions: Coronary Artery Disease

Summary: to examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon

to examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon. prospective, multicenter, randomized, single-blind, 70 patients. experimental intervention: predilatation of coronary de-novo stenosis followed by a sirolimus coated sequent®scb balloon (sirolimus 4.0 μg/mm²). control intervention: predilatation of coronary de-novo stenosis followed by a sequent®please or sequent®please neo balloon (paclitaxel 3.0 μg/mm²). follow-up per patient: 30 days telephone call; 6 months angiographic + 12 months. clinical follow up.

Eligibility criteria:
inclusion criteria: * clinical evidence of stable or unstable angina or a positive functional study * patients with significant coronary de-novo stenosis (≥ 70% diameter stenosis or intermediate ≥ 50% to \<70% diameter stenosis with positive functional test or symptom of ischemia) * successful lesion preparation (no flow-limiting dissection or a residual stenosis \> 30%) exclusion criteria: * acute myocardial infarction within the past 72 hours (stemi or nstemi) * intolerance and / or allergy to sirolimus * intolerance or allergy to paclitaxel and/or the delivery matrix (main ingredient: iopromide) * patients with an ejection fraction of \< 30 % * reference vessel diameter (rvd) \< 2.5 mm * contraindication for whichever necessary accompanying medication

Keywords: drug coated balloon paclitaxel sirolimus
pdl and fractional photothermolysis for postsurgical scars

Conditions: Scar

Summary: this is a two part study to evaluate the efficacy of early combined pdl (pulsed dye laser) and fractional photothermolysis in the cosmetic improvement of post surgical scars.all subjects will be offered at the time of the dermatologic procedure, an option to treat the post surgical scars with early combined pdl and fractional photothermolysis. part a is a non-randomized study design and subjects will have the choice of whether or not they will receive treatment. in part b, subjects will be randomized in a 2:1 treatment vs. control design. the experimental group will have a total of 6 visits: 1 standard of care suture removal visit, 3 treatment visits and 2 follow up visits. the control group will have 3 visits: 1 standard of care suture removal visit and 2 follow up visits. subjects currently living in the chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment. this study is a pilot study designed to determine feasibility of this procedure.


Eligibility criteria:
inclusion criteria: 1. males or females ≥ 18 years old 2. fitzpatrick skin types i-vi 3. subjects are in good health as judged by the investigator. 4. subjects who have received dermatologic surgery procedure of the trunk or extremities closed with complex primary closure with subcuticular running suture removed at 2-3 weeks. 5. subjects applying topical retinoids, must discontinue one week prior to treatment. 6. subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator. exclusion criteria: 1. history of recurrent facial or labial herpes simplex infection 2. subjects applying topical retinoids, must discontinue one week prior to treatment. 3. subjects with a history of hypertrophic scars or keloids 4. pregnant or breast feeding 5. uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations. 6. subjects who are unable to understand the protocol or give informed consent. 7. subjects who in the opinion of the investigator are likely to have exaggerated scarring with laser treatments.
safety and efficacy study of rev131 in the treatment of ocular inflammation after cataract surgery

Conditions: Ocular Inflammation

Summary: the purpose of this study is to evaluate the safety and effectiveness of three concentrations of rev131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an fda approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.


Eligibility criteria:
inclusion criteria: * be male or female who has undergone unilateral cataract extraction by phacoemulsification (phaco) method with implantation of a posterior chamber intraocular lens exclusion criteria: * have unstable glaucoma * have an active bacterial and/or viral infection * use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment and for the duration of the study.
intraocular steroid after cataract surgery study

Conditions: Cataract

Summary: the use of one dose of an antibiotic and steroid injected into the eye at the end of cataract surgery is as safe and effective as the post operative use of eyedrops after cataract surgery.

this prospective randomized controlled trial included 80 eyes of 40 patients having routine phacoemulsification of cataract. patients between 40 and 80 years of age who met enrollment criteria, required cataract surgery in both eyes, and agreed to participate, were enrolled in the study over a nine month period in 2006 at the office of one cataract surgeon. eyes were randomly assigned to receive either the eye drop or injection protocol on the initial consultative visit. all surgery was preformed by one surgeon (jgs) using topical anesthesia, the infiniti phacoemulsification system (alcon) and an acrysof sn60wf (alcon) intraocular lens. the fellow eye was operated upon using the same technique and instrumentation two weeks later and was assigned to the group opposite the first eye. all eyes were examined by the operating surgeon at days 1, 8, 15, 30 and 90 postoperatively with uncorrected visual acuity, best corrected visual acuity, intraocular pressure, corneal edema, anterior chamber cell and flare recorded.

Eligibility criteria:
inclusion criteria: * inclusion criteria for patients to enter the study included age 40 to 80 years, clinically significant cataract in both eyes, the patient's willingness to enter the study and have cataract surgery preformed on each eye in a sequentially within a two or three week time frame. exclusion criteria: * exclusion criteria included a history of glaucoma, retinopathy of any type, pseudoexfoliation, other significant ocular co morbidity and systemic diabetes.

Keywords: intraocular triamcinolone gatifloxicin inflammation visual acuity
effect of intraoperative dexmedetomidine on postoperative delirium in elderly patients undergoing major abdominal surgery

Conditions: Delirium in Old Age

Summary: to observe the effect of intraoperative dexmedetomidine on the incidence of postoperative delirium, postoperative analgesic drug requirements and pain scores in elderly patients undergoing major abdominal surgery.

this study is a multicenter, randomized, double-blind, placebo-controlled trial. three hundred patients undergoing elective major abdominal surgery were randomized to the intervention and control groups. patients in the intervention group were given a loading dose of 0.6 μg/kg of dexmedetomidine by intravenous infusion within 10 minutes after intubation, followed by a continuous infusion at a rate of 0.4 μg/kg/h until 30 min before the end of the procedure; patients in the control group were given an equal volume of saline. data were collected at 1-5 days and 1 month postoperative follow-up.

Eligibility criteria:
inclusion criteria: * patients over 65 years old * patients undergoing elective major abdominal surgery * written informed consent was obtained exclusion criteria: * patients with severe preoperative cognitive impairment (mmse ≤ 20) who are unable to undergo a follow-up evaluation. * patients with history of psychiatric or neurological disorders. * patients with body mass index ≤ 18 or ≥ 30 * patients with severe bradycardia (heart rate less than 40 beats per minute) * patients with pathological sinus node syndrome or grade 2 or greater av block * patients with severe hepatic or renal insufficiency. * patients with severe hypertension (systolic blood pressure ≥ 180 mmhg or diastolic blood pressure ≥ 110 mmhg)

Keywords: dexmedetomidine